MedTrace Logo

Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast

NCT06340984 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-04-03

No results posted yet for this study

Summary

The aim of this study is to:

1. Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne vulgaris and compare it to control group
2. Evaluate its role in acne pathogenesis and its correlation with acne vulgaris severity
3. Evaluate the effect of Montelukast on serum (sICAM-1) level in acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

DRUG

Montelukast 10 Mg Oral Tablet

group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Hassan Mohammed Ibrahim, Assistant Professor · South Valley University

  • Abdulrahman Abdul Hamid Alsaied, Professor · South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-11-30
Completion
2025-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06340984 on ClinicalTrials.gov